Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday

Shares of precious-metals-related companies are trading higher alongside gains in gold and silver prices as Treasury yields and the U.S. dollar decline following the Treasury Department’s announcement that it would double the size of liquidity-support buyback operations for longer-dated bonds.

Applied Optoelectronics, SanDisk, Seagate And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Stock futures mixed, Nasdaq 100 down 100 points. Applied Optoelectronics falls after announcing $600M offering. Other pre-market losers include RFAI, ZSTK, ZKH, JMIA, VALN, MFI, COHR, SNDK, AXTI, ASTL, LITE, STX.

Shares of steel and aluminum-related companies are trading lower amid expectations for progress on a U.S.-Canada trade agreement before the weekend. A trade framework may lessen investor interest in finished metals producers that would have benefitted from domestic U.S. production under continued tariffs.

Algoma Steel shares are trading higher after President Trump said in a social media post that the U.S. and Canada reached an agreement to delay 50% import tariffs on Canadian goods for three days.

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

$7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, Challenges

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.